The therapeutic promises of NAD+ boosters
- PMID: 34233170
- DOI: 10.1016/j.cmet.2021.06.008
The therapeutic promises of NAD+ boosters
Abstract
Numerous preclinical studies implicate the decline in NAD+ signaling in developing aging- and obesity-associated metabolic disorders. Yoshino et al. (2021) now provide the clinical evidence that an NAD+ booster increases muscle insulin sensitivity in postmenopausal prediabetic women, validating the therapeutic promises of NAD+ boosters in humans.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.C. is an inventor of patents on the use of NAD boosters and sirtuin activators for stem cell aging and tissue degenerative diseases.
Comment on
-
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.Science. 2021 Jun 11;372(6547):1224-1229. doi: 10.1126/science.abe9985. Epub 2021 Apr 22. Science. 2021. PMID: 33888596 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
